Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252009 | 0.92 | MAPK1 (0.43) | MAPK1TRPV1CNR2MMP13DGAT1 | |
| SCHEMBL8255410 | 0.91 | TRPV1 (0.44) | MAPK1TRPV1CNR2MMP13DGAT1 | |
| SCHEMBL10165685 | 0.84 | MAPK1 (0.46) | MAPK1CNR2MMP13DGAT1HDAC3 | |
| SCHEMBL10165955 | 0.78 | MMP13 (0.64) | MAPK1TRPV1CNR2MMP13DGAT1 | |
| SCHEMBL10162467 | 0.77 | MAPK1 (0.43) | MAPK1MMP13DGAT1HDAC3HDAC1 | |
| SCHEMBL10165461 | 0.77 | MAPK1 (0.46) | MAPK1CNR2MMP13DGAT1HDAC3 | |
| SCHEMBL10166552 | 0.76 | PHGDH (0.47) | MMP13PTGER4 | |
| SCHEMBL8256442 | 0.76 | MMP13 (0.67) | MAPK1TRPV1CNR2MMP13DGAT1 | |
| SCHEMBL10164579 | 0.76 | MAPK1 (0.45) | MAPK1CNR2MMP13DGAT1HDAC3 | |
| SCHEMBL8187623 | 0.75 | KDM4E (0.48) | MMP13PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | MAPK1 2860/4885TRPV1 2157/4885CNR2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.